HIV vaccine found to cure 90% of human recipients.
source: http://ki.se/ki/jsp/polop...15986&l=en
Posted in: News

A Swedish HIV vaccine study conducted by researchers at Karolinska Institutet (KI), Karolinska University Hospital and the Swedish Institute for Infectious Disease Control (SMI) has produced surprisingly good results. Over 90 per cent of the subjects in the phase 1 trials developed an immune response to HIV.

“Never has such a good result been seen with a vaccine of this type,” says Professor Eric Sandström, Chief Physician at Karolinska University Hospital.

A vaccine developed by SMI scientists has now undergone the first clinical study on healthy individuals in Sweden in order to examine its safety and different methods of administration. The vaccine is what is known as a genetic vaccine, which uses parts of the virus DNA to stimulate the rapid endogenous production of the proteins for which the injected DNA codes.

The trial subjects were vaccinated on three occasions with this vaccine using a needle-free method of injection. In order to enhance the effect, the researchers also gave the subjects a fourth dose of a vaccine in which parts of the HIV virus DNA had been integrated into another virus (vaccinia = the cowpox virus). This vaccine-based HIV vaccine is produced by the USA’s National Institutes of Health and was donated for use in this Swedish study.

“Our vaccine is designed in such a way that it’s able to protect against many of the circulating HIV types in Africa and the West,” says Professor Britta Wahren at the SMI/KI.

Over 90 per cent of the trial subjects developed an immune response to HIV, and the vaccines have been tolerated well.

Scientists now hope to follow up the Swedish study with a larger phase 1 - phase 2 study in Tanzania, planned to commence this autumn, in order to corroborate the Swedish results on African subjects and to help train Tanzanians to carry out parts of the study, including sophisticated laboratory examinations, on site.
For further information, please contact:
Gunnel Biberfeld, Professor of Immunology, SMI and KI. Phone: +46-8-457 26 60, +46-73-346 26 60. E-mail: gunnel.biberfeld@smi.ki.se

Eric Sandström, Professor of Dermatovenerology, Chief Physician at Karolinska University Hospital. Phone: +46-8-616 25 71, +46-70-484 60 37. E-mail: eric.sandstrom@karolinska.se

Britta Wahren, Professor of Virology, SMI and KI. Phon 46-8-457 26 30, +46-70-674 15 27. E-mail: britta.wahren@smi.ki.se

_____

That is encouraging news, but I read that as a vaccine, not a cure. The vaccine was tested on healthy individuals to determine an immune respone to the virus.

First of all, immunizations do not yield "cures". This will not cure anyone with the disease.

Second of all, over 90% of patients developed an immune response to the vaccine means absolutely nothing because the efficacy of this response at actually preventing transmission has NOT yet been tested.
[Edited 11/7/07 11:01am]

This needs to be corrected it is not a cure but a trial vaccine.


very misleading title.